alkaline phosphatase, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, alkaline phosphatase

Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E 1987 Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664.
Aasheim ET, Hofso D, Hjelmesaeth J, Birkeland KI, Bohmer T 2008 Vitamin status in morbidly obese patients: a cross-sectional study. Am. J. Clin. Nutr. 87: 362-369. *
Abboud J, Ghaith GM, Gordon SC 2002 Primary sclerosing cholangitis: a revised clinical spectrum. Am. J. Gastroenterol. 97: S103. *
Abdalian R, Dhar P, Jhaveri K, Haider M, Guindi M, Heathcote EJ 2008 Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: evaluating the role of routine magnetic resonance imaging. Hepatology 47: 949-957. *
Abedin M, Lim J, Tang TB, Park D, Demer LL, Tintut Y 2006 n-3 Fatty acids inhibit vascular calcification via the p38-MAPK and peroxisome proliferator-activated receptor-gamma pathways. Circ. Res. 98: 727-729. *
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR 2006 Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 40: 55-63.
Accatino L, Figueroa C, Pizarro M, Solis N 1995 Enhanced biliary excretion of canalicular membrane enzymes in estrogen-induced and obstructive cholestasis, and effects of different bile acids in the isolated perfused rat liver. J. Hepatol. 22: 658-670. *
Accatino L, Pizarro M, Solis N, Koenig CS, Vollrath V, Chianale J 1996 Modulation of hepatic content and biliary excretion of P-glycoproteins in hepatocellular and obstructive cholestasis in the rat. J. Hepatol. 25: 349-361. *
Adams LA, Zein CO, Angulo P, Lindor KD 2004 A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 99: 2365-2368. *
Aghai ZH, Mudduluru M, Nakhla TA, Amendolia B, Longo D, Kemble N, Kaki S, Sutsko R, Saslow JG, Stahl GE 2006 Fluconazole prophylaxis in extremely low birth weight infants: association with cholestasis. J. Perinatol. 26: 550-555.
Aitola P, Karvonen AL, Matikainen M 1994 Prevalence of hepatobiliary dysfunction in patients with ulcerative colitis. Ann. Chir. Gynaecol. 83: 275-278.
Aizawa K, Kawaguchi S, Doi M, Mizuno W, Uragami K, Oka T, Miyamoto H, Itoh H, Nishioka S 1992 A case of primary intrahepatic sclerosing cholangitis (PISC) complicated with atypical biliary epithelial proliferation. Intern. Med. 31: 114-121. *
Akiba Y, Mizumori M, Guth PH, Engel E, Kaunitz JD 2007 Duodenal brush border intestinal alkaline phosphatase activity affects bicarbonate secretion in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1223-G1233. *
Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A 2006 Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med. J. 47: 147-151. *
Al-Masri AN, Flemming P, Rodeck B, Melter M, Leonhardt J, Petersen C 2006 Expression of the interferon-induced Mx proteins in biliary atresia. J. Pediatr. Surg. 41: 1139-1143.
Alarcon-Corredor OM, Alfonso R 2007 Clinical and biochemical alterations in rats treated with high doses of vitamin A. Arch. Latinoam. Nutr. 57: 224-230.
Aldemir M, Faruk Gey I K M, Faruk Kokoglu O, Buyukbayram HI, Hosoglu SI, Yagmur Y 2003 Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats. ANZ J. Surg. 73: 722-726. *
Aleryani SL, Cluette-Brown JE, Khan ZA, Hasaba H, Lopez de Heredia L, Laposata M 2005 Fatty acid methyl esters are detectable in the plasma and their presence correlates with liver dysfunction. Clin. Chim. Acta 359: 141-149. *
Alkhoury F, Malo MS, Mozumder M, Mostafa G, Hodin RA 2005 Differential regulation of intestinal alkaline phosphatase gene expression by Cdx1 and Cdx2. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G285-G290. *
Almasio P, Bortolini M, Pagliaro L, Coltorti M 1990 Role of S-adenosyl-L-methionine in the treatment of intrahepatic cholestasis. Drugs 40 Suppl. 3: 111-123.
Alonso L AG 2006 Effect of pregnancy on pre-existing liver disease physiological changes during pregnancy. Ann. Hepatol. 5: 184-186. *
Alpers DH, Mahmood A, Engle M, Yamagishi F, DeSchryver-Kecskemeti K 1994 The secretion of intestinal alkaline phosphatase (IAP) from the enterocyte. J. Gastroenterol. 29 Suppl. 7: 63-67.
Alric L, Thebault S, Selves J, Peron JM, Mejdoubi S, Fortenfant F, Vinel JP 2007 Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol. Clin. Biol. 31: 11-16. *
Alvaro D, Benedetti A, Marucci L, Delle Monache M, Monterubbianesi R, Di Cosimo E, Perego L, Macarri G, Glaser S, Le Sage G, Alpini G 2000 The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 32: 174-184. *
Alvaro D, Piat C, Francia C, Franchitto A, Furfaro S, Valente C, Capocaccia L, Gaudio E 1996 Ultrastructural features of danazol-induced cholestasis: a case study. Ultrastruct. Pathol. 20: 491-495.
Alwayn IP, Verbesey JE, Kim S, Roy R, Arsenault DA, Greene AK, Novak K, Laforme A, Lee S, Moses MA, Puder M 2008 A critical role for matrix metalloproteinases in liver regeneration. J. Surg. Res. 145: 192-198. *
Alzahrani AS, Sheef MA 2008 Severe primary hyperparathyroidism masked by asymptomatic celiac disease. Endocr. Pract. 14: 347-350.
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG 1985 The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223.
Ameen NA, Figueroa Y, Salas PJ 2001 Anomalous apical plasma membrane phenotype in CK8-deficient mice indicates a novel role for intermediate filaments in the polarization of simple epithelia. J. Cell Sci. 114: 563-575. *
Ameen NA, Salas PJ 2000 Microvillus inclusion disease: a genetic defect affecting apical membrane protein traffic in intestinal epithelium. Traffic 1: 76-83. *
American Gastroenterological Association 2002 American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123: 1364-1366. *
Andrei VE, Schein M, Margolis M, Rucinski JC, Wise L 1998 Liver enzymes are commonly elevated following laparoscopic cholecystectomy: is elevated intra-abdominal pressure the cause? Dig. Surg. 15: 256-259.
Angulo P, Batts KP, Jorgensen RA, LaRusso NA, Lindor KD 2000 Oral budesonide in the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2333-2337. *
Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, Lange SM, Anderson ML, Mahoney DW, Lindor KD 1999 Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J. Hepatol. 30: 830-835. *
Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD 2000 Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 31: 318-323. *
Angulo P, Jorgensen RA, Kowdley KV, Lindor KD 2008 Silymarin in the treatment of patients with primary sclerosing cholangitis: an open-label pilot study. Dig. Dis. Sci. 53: 1716-1720. *
Angulo P, Lindor KD 1999 Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570. *
Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, Dickson ER 1999 Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 19: 115-121. *
Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD 2000 Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 32: 897-900. *
Antonio Olivera M, Zapata L, Kaplan M, Bobadilla J, Corte G, de la Mora G, Uribe M, Cabiedes J, Dehesa M, Kershenobich D 1993 Prevalence of antinuclear antibodies in primary biliary cirrhosis, with negative antimitochondrial antibodies. Rev. Gastroenterol. Mex. 58: 220-222.
Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, Moriyama M, Iwasaki A, Sugitani M, Arakawa Y 2004 PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J. Gastroenterol. 39: 490-495. *
Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalcin S, Akan H 2005 Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin. Transplant. 19: 798-803. *
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G 2000 Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J. Intern. Med. 247: 63-70. *
Armagan O, Uz T, Tascioglu F, Colak O, Oner C, Akgun Y 2005 Serological screening for celiac disease in premenopausal women with idiopathic osteoporosis. Clin. Rheumatol. 24: 239-243. *
Arrese M, Pizarro M, Solis N, Koenig C, Accatino L 1995 Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration. Biochem. Pharmacol. 50: 1223-1232.
Arulventhan R, Larcos G, Gruenewald S, Farrell G 2006 Primary sclerosing cholangitis: correlation of hepatobiliary scintigraphy with clinical and laboratory status. Australas. Radiol. 50: 330-334.
Aung CS, Faddy HM, Lister EJ, Monteith GR, Roberts-Thomson SJ 2006 Isoform specific changes in PPARalpha and beta in colon and breast cancer with differentiation. Biochem. Biophys. Res. Commun. 340: 656-660. *
Avezov SA, Mansurov FKh 2004 Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 55-58.
Avezov SA, Mansurova FKh 2004 Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 46-49.
Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S 2007 Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410. *
Azer SA, Canfield PJ, Stacey NH 1995 Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. J. Gastroenterol. Hepatol. 10: 261-269.
Bachs L, Pares A, Elena M, Piera C, Rodes J 1992 Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080.
Bachs O, Enrich C, Soriano M, Pinol R, Domingo J 1985 Induction of plasma membrane alkaline phosphatase in rat liver. Cell Biochem. Funct. 3: 95-100.
Baghdasaryan A, Fickert P, Fuchsbichler A, Silbert D, Gumhold J, Horl G, Langner C, Moustafa T, Halilbasic E, Claudel T, Trauner M 2008 Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. Liver Int. 28: 948-958. *
Baines M 1980 Clinical usefulness of the simultaneous localisation of the isoenzymes of alkaline phosphate and gamma-glutamyl transferase. Ann. Clin. Biochem. 17: 20-25.
Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH 1993 Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398.
Balasubramaniam K, Wiesner RH, LaRusso NF 1988 Primary sclerosing cholangitis with normal serum alkaline phosphatase activity. Gastroenterology 95: 1395-1398.
Balistreri WF 1997 Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589.
Balistreri WF 2003 Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Ballester I, Daddaoua A, Lopez-Posadas R, Nieto A, Suarez MD, Zarzuelo A, Martinez-Augustin O, de Medina FS 2007 The bisphosphonate alendronate improves the damage associated with trinitrobenzenesulfonic acid-induced colitis in rats. Br. J. Pharmacol. 151: 206-215. *
Ballester I, Gonzalez R, Nieto A, Zarzuelo A, Sanchez de Medina F 2005 Monochloramine induces acute and protracted colitis in the rat: response to pharmacological treatment. Life Sci. 76: 2965-2980. *
Baltes S, Nau H, Lampen A 2004 All-trans retinoic acid enhances differentiation and influences permeability of intestinal Caco-2 cells under serum-free conditions. Dev. Growth Differ. 46: 503-514.
Balzer K, Hotz J, Goebell H 1980 Eosinophilia as a diagnostic clue to primary sclerosing cholangitis. Z. Gastroenterol. 18: 89-93.
Ban Y, Ban Y, Taniyama M, Katagiri T 2000 Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 375-380.
Ban Y, Ban Y, Taniyama M, Katagiri T 2000 Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 10: 475-480.
Bandyopadhyay SK, Bandyopadhyay R, Dutta A 2006 Primary amyloidosis presenting as intrahepatic cholestasis. Indian J. Pathol. Microbiol. 49: 557-559.
Bansi D, Chapman R, Fleming K 1996 Antineutrophil cytoplasmic antibodies in chronic liver diseases: prevalence, titre, specificity and IgG subclass. J. Hepatol. 24: 581-586. *
Bansi DS, Bauducci M, Bergquist A, Boberg K, Broome U, Chapman R, Fleming K, Jorgensen R, Lindor K, Rosina F, Schrumpf E 1997 Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. Eur. J. Gastroenterol. Hepatol. 9: 575-580.
Bansi DS, Chapman RW, Fleming KA 1996 Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8: 881-885.
Bansi DS, Fleming KA, Chapman RW 1996 Importance of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and ulcerative colitis: prevalence, titre, and IgG subclass. Gut 38: 384-389. *
Bansi DS, Lo S, Chapman RW, Fleming KA 1996 Absence of antineutrophil cytoplasmic antibodies in relatives of UK patients with primary sclerosing cholangitis and ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8: 111-116.
Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
Barton CC, Ganey PE, Roth RA 2000 Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol. Sci. 58: 208-215. *
Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA 2000 Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol. Sci. 55: 444-452. *
Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP 2006 Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J. Gastroenterol. 12: 5680-5686. *
Basarir Ozkan T, Mistik R, Dikici B, Ozturk Nazlioglu H 2007 Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis. BMC Gastroenterol. 7: 9. *
Baslund B, Petersen J, Permin H, Wiik A, Wieslander J 1994 Measurements of proteinase 3 and its complexes with alpha 1-proteinase inhibitor and anti-neutrophil cytoplasm antibodies (ANCA) in plasma. J. Immunol. Methods 175: 215-225.
Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J 2005 Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 22: 775-782. *
Bates JM, Akerlund J, Mittge E, Guillemin K 2007 Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota. Cell Host Microbe 2: 371-382. *
Bates JM, Mittge E, Kuhlman J, Baden KN, Cheesman SE, Guillemin K 2006 Distinct signals from the microbiota promote different aspects of zebrafish gut differentiation. Dev. Biol. 297: 374-386. *
Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S 1989 Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis. Hepatology 10: 414-419.
Batta AK, Salen G, Mirchandani R, Tint GS, Shefer S, Batta M, Abroon J, O'Brien CB, Senior JR 1993 Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 88: 691-700.
Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F 1993 Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J. Hepatol. 17: 332-338.
Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr 2003 Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch. Intern. Med. 163: 615-620. *
Beau P, Barrioz T, Ingrand P 1994 Total parenteral nutrition-related cholestatic hepatopathy, is it an infectious disease? Gastroenterol. Clin. Biol. 18: 63-67.
Beau P, Labat-Labourdette J, Ingrand P, Beauchant M 1994 Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J. Hepatol. 20: 240-244.
Belaguli NS, Zhang M, Rigi M, Aftab M, Berger DH 2007 Cooperation between GATA4 and TGF-beta signaling regulates intestinal epithelial gene expression. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1520-G1533. *
Ben-Ari Z, Dhillon AP, Sherlock S 1993 Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18: 10-15.
Ben-Ari Z, Schmilovotz-Weiss H, Belinki A, Pappo O, Sulkes J, Neuman MG, Kaganovsky E, Kfir B, Tur-Kaspa R, Klein T 2003 Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J. Intern. Med. 254: 168-175. *
Ben-Ari Z, Weiss-Schmilovitz H, Sulkes J, Brown M, Bar-Nathan N, Shaharabani E, Yussim A, Shapira Z, Tur-Kaspa R, Mor E 2004 Serum cholestasis markers as predictors of early outcome after liver transplantation. Clin. Transplant. 18: 130-136.
Bengoa JM, Hanauer SB, Sitrin MD, Baker AL, Rosenberg IH 1985 Pattern and prognosis of liver function test abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology 5: 79-84.
Bentala H, Verweij WR, Huizinga-Van der Vlag A, van Loenen-Weemaes AM, Meijer DK, Poelstra K 2002 Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide. Shock 18: 561-566. *
Bergasa NV 2005 The pruritus of cholestasis. J. Hepatol. 43: 1078-1088. *
Bergasa NV, Jones A, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH 1996 Pilot study of low dose oral methotrexate treatment for primary biliary cirrhosis. Am. J. Gastroenterol. 91: 295-299.
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *
Berger J, Garattini E, Hua JC, Udenfriend S 1987 Cloning and sequencing of human intestinal alkaline phosphatase cDNA. Proc. Natl. Acad. Sci. U.S.A. 84: 695-698. *
Bergquist A, Said K, Broome U 2007 Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand. J. Gastroenterol. 42: 88-93. *
Bernal-Reyes R, Escudero RB 2002 Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report. Rev. Gastroenterol. Mex. 67: 70-75.
Bertolami MC 2005 Mechanisms of hepatotoxicity. Arq. Bras. Cardiol. 85 Suppl. 4: 25-27.
Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G 1992 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: 707-714.
Beukers R, van Zanten RA, Schalm SW 1992 Serial determination of type III procollagen amino propeptide serum levels in patients with histologically progressive and non-progressive primary biliary cirrhosis. J. Hepatol. 14: 22-29.
Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W 2003 Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J. Pharmacol. Exp. Ther. 307: 737-744. *
Bharucha AE, Jorgensen R, Lichtman SN, LaRusso NF, Lindor KD 2000 A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 95: 2338-2342. *
Bhat MK, Ashizawa K, Cheng SY 1994 Phosphorylation enhances the target gene sequence-dependent dimerization of thyroid hormone receptor with retinoid X receptor. Proc. Natl. Acad. Sci. U.S.A. 91: 7927-7931. *
Bhatia AL, Sharma A, Patni S, Sharma AL 2007 Prophylactic effect of flaxseed oil against radiation-induced hepatotoxicity in mice. Phytother. Res. 21: 852-859. *
Bhattacharya A, Rahman M, Sun D, Fernandes G 2007 Effect of fish oil on bone mineral density in aging C57BL/6 female mice. J. Nutr. Biochem. 18: 372-379. *
Birketvedt GS, Berg KJ, Fausa O, Florholmen J 2000 Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis. Inflamm. Bowel Dis. 6: 275-279. *
Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C 1997 Reduced bone density in patients with inflammatory bowel disease. Gut 40: 228-233. *
Bjornsson E, Kilander A, Olsson R 1999 CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver 19: 501-508. *
Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R 2004 Dominant strictures in patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 99: 502-508. *
Bjornsson E, Nordlinder H, Olsson R 2006 Clinical characteristics and prognostic markers in disulfiram-induced liver injury. J. Hepatol. 44: 791-797. *
Blanchard RK, Cousins RJ 2000 Regulation of intestinal gene expression by dietary zinc: induction of uroguanylin mRNA by zinc deficiency. J. Nutr. 130: 1393S-1398S. *
Blanco PG, Zaman MM, Junaidi O, Sheth S, Yantiss RK, Nasser IA, Freedman SD 2004 Induction of colitis in cftr-/- mice results in bile duct injury. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G491-G496. *
Blejter J, Weller S, Pace R, Cusumano H, Giambini D 2008 Autoimmune pancreatitis: an adolescent case and review of literature. J. Pediatr. Surg. 43: 1368-1372.
Bloomer JR, Boyer JL 1975 Phenobarbital effects in cholestatic liver diseases. Ann. Intern. Med. 82: 310-317.
Boberg KM, Egeland T, Schrumpf E 2003 Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand. J. Gastroenterol. 38: 991-995. *
Boberg KM, Fausa O, Haaland T, Holter E, Mellbye OJ, Spurkland A, Schrumpf E 1996 Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 23: 1369-1376. *
Bogdanovic M, Bulat P 2008 Biliary function in workers occupationally exposed to aluminium dust and fumes. Arh. Hig. Rada. Toksikol. 59: 135-139.
Boki KA, Dourakis SP 1995 Polymyositis associated with primary biliary cirrhosis. Clin. Rheumatol. 14: 375-378.
Bonis PA, Kaplan M 1999 Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 117: 395-399. *
Bonkovsky HL, Hawkins M, Steinberg K, Hersh T, Galambos JT, Henderson JM, Millikan WJ, Galloway JR 1990 Prevalence and prediction of osteopenia in chronic liver disease. Hepatology 12: 273-280.
Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M 2008 Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos. Int. Jul 4 [Epub ahead of print].
Borgognone M, Perez LM, Basiglio CL, Ochoa JE, Roma MG 2005 Signaling modulation of bile salt-induced necrosis in isolated rat hepatocytes. Toxicol. Sci. 83: 114-125. *
Borini P, Guimaraes RC 2003 Noninvasive classification of liver disease in asymptomatic and oligosymptomatic male alcoholics. Braz. J. Med. Biol. Res. 36: 1367-1373. *
Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A, Mebazaa A 2003 Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol. Clin. Biol. 27: 901-907.
Bowden SA, Robinson RF, Carr R, Mahan JD 2008 Prevalence of vitamin D deficiency and insufficiency in children with osteopenia or osteoporosis referred to a pediatric metabolic bone clinic. Pediatrics 121: e1585-e1590. *
Bower RH 1983 Hepatic complications of parenteral nutrition. Semin. Liver Dis. 3: 216-224.
Boyer JL 2007 New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. J. Hepatol. 46: 365-371. *
Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O 2002 Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med. Pediatr. Oncol. 38: 178-182. *
Brensilver HL, Kaplan MM 1975 Significance of elevated liver alkaline phosphatase in serum. Gastroenterology 68: 1556-1562.
Breuer W, Slotki IN, Ausiello DA, Cabantchik IZ 1993 Induction of multidrug resistance downregulates the expression of CFTR in colon epithelial cells. Am. J. Physiol. 265: C1711-C1715.
Brock DJ, Clarke HA, Barron L 1988 Prenatal diagnosis of cystic fibrosis by microvillar enzyme assay on a sequence of 258 pregnancies. Hum. Genet. 78: 271-275.
Brocklehurst D, Wilde CE, Doar JW 1978 The incidence and likely origins of serum particulate alkaline phosphatase and lipoprotein-X in liver disease. Clin. Chim. Acta 88: 509-515.
Brohult J, Fridell E, Sundblad L 1977 Studies on alkaline phosphatase isoenzymes. Relation to gamma-glutamyltransferase and lactate dehydrogenase isoenzymes. Clin. Chim. Acta 76: 205-211.
Broome U, Lindberg G, Lofberg R 1992 Primary sclerosing cholangitis in ulcerative colitis - a risk factor for the development of dysplasia and DNA aneuploidy? Gastroenterology 102: 1877-1880.
Brostoff JM, Rashid S, McCrea D 2008 Primary biliary cirrhosis with a normal alkaline phosphatase: a case report. Cases J. 1: 33. *
Buckingham RE 2005 Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170.
Bucuvalas JC, Bove KE, Kaufman RA, Gilchrist MJ, Oldham KT, Balistreri WF 1985 Cholangitis associated with Cryptococcus neoformans. Gastroenterology 88: 1055-1059.
Budillon G 1993 The epidemiology of cholestasis in hepatopathies. Ann. Ital. Med. Int. 8: 36S-40S.
Bueno MR, Daneri A, Armendariz-Borunda J 2000 Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 33: 915-925. *
Bugeac N, Pacht A, Mandel H, Iancu T, Tamir A, Srugo I, Shaoul R 2007 The significance of isolated elevation of serum aminotransferases in infants and young children. Arch. Dis. Child. 92: 1109-1112.
Burlina A, Bugiardini R 1978 Studies on alkaline phosphatase isoenzymes in hepatic diseases. Relation to gamma-glutamyltransferase. Clin. Chim. Acta 85: 49-54.
Burt AD 2004 Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355. *
Buscher HP, Zietzschmann Y, Gerok W 1993 Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J. Hepatol. 18: 9-14.
Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E 2006 Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr. Res. 60: 24-29. *
Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manuokian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G 2005 CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54: 78-86. *
Caballeria L, Pares A, Rodes J 1999 Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85. *
Cagatay Y, Gul A, Cagatay A, Kamali S, Karadeniz A, Inanc M, Ocal L, Aral O, Konice M 2007 Adult-onset Still's disease. Int. J. Clin. Pract. May 18 [Epub ahead of print].
Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, Rowley M, Reddy KR, Coppel R, Jeffers LJ, et al 1992 Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 16: 899-905.
Cameron JL, Gayler BW, Sanfey H, Milligan F, Kaufman S, Maddrey WC, Herlong HF 1984 Sclerosing cholangitis. Anatomical distribution of obstructive lesions. Ann. Surg. 200: 54-60. *
Camuesco D, Comalada M, Concha A, Nieto A, Sierra S, Xaus J, Zarzuelo A, Galvez J 2006 Intestinal anti-inflammatory activity of combined quercitrin and dietary olive oil supplemented with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, in rats with DSS-induced colitis. Clin. Nutr. 25: 466-476.
Cangemi JR, Wiesner RH, Beaver SJ, Ludwig J, MacCarty RL, Dozois RR, Zinsmeister AR, LaRusso NF 1989 Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology 96: 790-794.
Caparbo VF, Prada F, Silva CA, Regio PL, Pereira RM 2008 Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro". Clin. Rheumatol. Aug 7 [Epub ahead of print].
Cappell MS 1991 Hepatobiliary manifestations of the acquired immune deficiency syndrome. Am. J. Gastroenterol. 86: 1-15.
Caproni M, Torchia D, Schincaglia E, Volpi W, Frezzolini A, Schena D, Marzano A, Quaglino P, De Simone C, Parodi A, Barletta E, Fabbri P 2006 The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br. J. Dermatol. 154: 319-324. *
Carey HV, Martin SL 1996 Preservation of intestinal gene expression during hibernation. Am. J. Physiol. 271: G804-G813.
Carulli N, Loria P, Bertolotti M, Ponz de Leon M, Menozzi D, Medici G, Piccagli I 1984 Effects of acute changes of bile acid pool composition on biliary lipid secretion. J. Clin. Invest. 74: 614-624. *
Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR 2003 Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J. Clin. Gastroenterol. 36: 120-125.
Castro-e-Silva Junior O, Franco CF, Souza ME, Picinato MA, Santos JS, Ceneviva R 1990 Serum gamma-glutamyl transpeptidase in chronic extrahepatic cholestasis. Braz. J. Med. Biol. Res. 23: 515-518.
Chamuleau RA, Diekman MJ, Bos PJ, Smitt JH, Bosma A, Schellekens PT 1992 Reappearance of vanished bile ducts. Hepatogastroenterology 39: 523-524.
Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK 2005 Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment. Pharmacol. Ther. 21: 217-226. *
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S 1980 Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21: 870-877. *
Chapman RW, Burroughs AK, Bass NM, Sherlock S 1981 Long-standing asymptomatic primary sclerosing cholangitis: report of three cases. Dig. Dis. Sci. 26: 778-782.
Charatcharoenwitthaya P, Levy C, Angulo P, Keach J, Jorgensen R, Lindor KD 2007 Open-label pilot study of folic acid in patients with nonalcoholic steatohepatitis. Liver Int. 27: 220-226. *
Charatcharoenwitthaya P, Lindor KD 2007 Primary sclerosing cholangitis: patients with a rising alkaline phosphatase at annual follow-up. Clin. Gastroenterol. Hepatol. 5: 32-36.
Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH 2007 Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 13: 1236-1245.
Chazouilleres O, Marteau P, Haniche M, Jian R, Poupon R 1996 Ileal absorption of bile acids in patients with chronic cholestasis: SeHCAT test results and effect of ursodeoxycholic acid (UDCA). Dig. Dis. Sci. 41: 2417-2422.
Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC 1990 Ursodeoxycholic acid for primary sclerosing cholangitis. J. Hepatol. 11: 120-123.
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R 1998 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28: 296-301. *
Chen J, Raymond K 2006 Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml).
Chen W, Gluud C 2003 Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626. *
Chen WD, Gluud C 2004 Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 3: CD004036. *
Chen YC, Huang LT, Wang SM, Tiao MM, Liu JW 2007 Acute hepatitis A infection in children: a 20-year experience of a medical center in Southern Taiwan. Acta Paediatr. Taiwan 48: 131-134.
Cheng Y, Ohlsson L, Duan RD 2004 Psyllium and fat in diets differentially affect the activities and expressions of colonic sphingomyelinases and caspase in mice. Br. J. Nutr. 91: 715-723. *
Cheong JY, Lee KM, Cho SW, Won JH, Kim JK, Wang HJ, Hahm KB, Kim JH 2005 Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol. Res. 32: 127-133.
Chernev K, Bakalov V 1985 Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46.
Chevailler A, Saint-Andre JP, Preel JL, Boyer J, Joubaud F, Hurez D 1988 Clinico-immunological profile of hepatic and extrahepatic diseases accompanied by anti-mitochondrial antibodies. Ann. Med. Interne. (Paris) 139: 19-23.
Chiarla C, Giovannini I, Siegel JH 2008 Patterns of correlation of plasma ceruloplasmin in sepsis. J. Surg. Res. 144: 107-110.
Chicharro M, Guarner L, Vilaseca J, Planas M, Malagelada J 2000 Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev. Esp. Enferm. Dig. 92: 68-77.
Chida K 1990 Histochemical and immunohistochemical study on the expression of alkaline phosphatase, gamma-glutamyl transpeptidase and alpha-fetoprotein during the process of rat hepatocyte proliferation. Kitasato Arch. Exp. Med. 63: 91-98.
Chien RN, Sheen IS, Chen TJ, Liaw YF 1992 A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121.
Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ 2005 In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352.
Chowdhary VR, Crowson CS, Poterucha JJ, Moder KG 2008 Liver involvement in systemic lupus erythematosus: case review of 40 patients. J. Rheumatol. Sep 15 [Epub ahead of print].
Choy MY, Walker-Smith JA, Williams CB, MacDonald TT 1990 Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 31: 1365-1370. *
Christensen E 2003 Prognosis of untreated primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 63. October 15-16. *
Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S 2007 Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 7: 44. *
Classen M, Gotze H, Richter HJ, Bender S 1987 Primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 6: 197-202.
Clements D, Rhodes JM, Elias E 1986 Severe bile duct lesions without biochemical evidence of cholestasis in a case of sclerosing cholangitis. J. Hepatol. 3: 72-74.
Coelho SM, Vaisman M, Carvalho DP 2005 Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr. Pharm. Des. 11: 2525-2531.
Cohen LB, Ambinder EP, Wolke AM, Field SP, Schaffner F 1985 Role of plasmapheresis in primary biliary cirrhosis. Gut 26: 291-294. *
Colombo C, Setchell KD, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, Giunta A 1990 Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J. Pediatr. 117: 482-489.
Colston K, Cleeve HJ 1986 Effect of triiodothyronine on intestinal and kidney isoenzymes of alkaline phosphatase and on vitamin D metabolism in adult female rats. Comp. Biochem. Physiol. B. 83: 681-684.
Coltorti M, Bortolini M, Di Padova C 1990 A review of the studies on the clinical use of S-adenosylmethionine (SAMe) for the symptomatic treatment of intrahepatic cholestasis. Methods Find. Exp. Clin. Pharmacol. 12: 69-78.
Compston JE, Horton LW, Thompson RP 1979 Treatment of osteomalacia associated with primary biliary cirrhosis with parenteral vitamin D2 or oral 25-hydroxyvitamin D3. Gut 20: 133-136. *
Compston JE, Thompson RP 1977 Intestinal absorption of 25-hydroxyvitamin D and osteomalacia in primary biliary cirrhosis. Lancet 1: 721-724.
Cooper JF, Brand EJ 1988 Symptomatic sclerosing cholangitis in patients with a normal alkaline phosphatase: two case reports and a review of the literature. Am. J. Gastroenterol. 83: 308-311.
Cornelis T, Claes K, Gillard P, Nijs E, Roskams T, Lombaerts R, Nevens F, Cassiman D 2008 Cholestatic liver disease in long-term infantile nephropathic cystinosis. J. Gastroenterol. Hepatol. 23: e428-e431. *
Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, Chazouilleres O, Poupon R 2008 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 48: 871-877.
Corpechot C, Benlian P, Barbu V, Chazouilleres O, Poupon RE, Poupon R 2001 Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J. Hepatol. 35: 324-328. *
Correa GH, Paredes SN 2007 Serum liver tests in patients treated with methotrexate: a retrospective analysis. Rev. Med. Chil. 135: 1002-1008.
Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, Sverzellati E, Tacchini G, Pierfranceschi MG, Carrara GC 1995 Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clin. Ter. 146: 367-372.
Crippin JS, Jorgensen RA, Dickson ER, Lindor KD 1994 Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am. J. Gastroenterol. 89: 47-50.
Crofton PM, Smith AF 1981 High-molecular-mass alkaline phosphatase in serum and bile: physical properties and relationship with other high-molecular-mass enzymes. Clin. Chem. 27: 860-866.
Crowe J, Christensen E, Doniach D, Popper H, Tygstrup N, Williams R 1985 Early features of primary biliary cirrhosis: an analysis of 85 patients. Am. J. Gastroenterol. 80: 466-468.
Cuff M, Dyer J, Jones M, Shirazi-Beechey S 2005 The human colonic monocarboxylate transporter isoform 1: its potential importance to colonic tissue homeostasis. Gastroenterology 128: 676-686. *
Cukovic-Cavka S 2003 Primary biliary cirrhosis. Acta Med. Croatica 57: 221-225.
Culafic D, Perisic M, Boricic I, Culafic-Vojinovic V, Vukcevic M 2007 Primary amyloidosis presenting with cholestasis and hyperkinetic portal hypertension. J. Gastrointestin. Liver Dis. 16: 201-204. *
Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW 2008 High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective? J. Hepatol. 48: 792-800. *
Culp JS, Hermodson M, Butler LG 1985 The active-site and amino-terminal amino acid sequence of bovine intestinal alkaline phosphatase. Biochim. Biophys. Acta 831: 330-334.
Cunnane SC, Manku MS, Horrobin DF 1979 The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 5: 403-414.
Czaja AJ 1999 Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70.
Czaja AJ 2004 Autoimmune hepatitis: clinical and laboratory diagnosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 52-54. *
Czaja AJ 2006 Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55.
Czaja AJ 2006 Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J. Hepatol. 44: 251-252. *
Czaja AJ 1998 Frequency and nature of the variant syndromes of autoimmune liver disease. Hepatology 28: 360-365. *
Czaja AJ, Carpenter HA, Lindor KD 1999 Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 30: 1381-1386. *
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 2000 Autoimmune cholangitis within the spectrum of autoimmune liver disease. Hepatology 31: 1231-1238. *
D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G 1995 Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig. Dis. Sci. 40: 2113-2116.
Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, Requena P, Zarzuelo A, Suarez MD, de Medina FS, Martinez-Augustin O 2007 Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J. Nutr. 137: 1222-1228. *
Daddaoua A, Puerta V, Zarzuelo A, Suarez MD, Sanchez de Medina F, Martinez-Augustin O 2005 Bovine glycomacropeptide is anti-inflammatory in rats with hapten-induced colitis. J. Nutr. 135: 1164-1170. *
Dahan S, Roda G, Pinn D, Roth-Walter F, Kamalu O, Martin AP, Mayer L 2008 Epithelial:lamina propria lymphocyte interactions promote epithelial cell differentiation. Gastroenterology 134: 192-203. *
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG 2005 Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414.
Dann AT, Kenyon AP, Seed PT, Poston L, Shennan AH, Tribe RM 2004 Glutathione S-transferase and liver function in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 40: 1406-1414. *
Das SN, Mohapatra B, Mohanty R, Dash PC, Kar K, Dash PK 2007 Malarial hepatitis as a component of multiorgan failure - a bad prognostic sign. J. Indian Med. Assoc. 105: 247-250.
Day AP, Feher MD, Chopra R, Mayne PD 1993 The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42: 839-842.
De Broe ME, Borgers M, Wieme RJ 1975 The separation and characterization of liver plasma membrane fragments circulating in the blood of patients with cholestasis. Clin. Chim. Acta 59: 369-372.
De Broe ME, Roels F, Nouwen EJ, Claeys L, Wieme RJ 1985 Liver plasma membrane: the source of high molecular weight alkaline phosphatase in human serum. Hepatology 5: 118-128.
de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ 2008 Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165. *
de Oliveira e Silva A, dos Santos TE, Cardoso ES, de Melo CR, Santo GC, dos Santos Junior ED, Cavichio MW, Kuramochi CA, Mattar RH, Teixeira AC, Leite CJ, D'Albuquerque LA 1998 Primary sclerosing cholangitis in children and adolescents. Arq. Gastroenterol. 35: 267-273.
Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O 1994 Sclerosing cholangitis in children. J. Pediatr. 124: 49-56.
Deeks ED, Lyseng-Williamson KA 2006 Oral paricalcitol. Treat. Endocrinol. 5: 319-325.
Deems RO, Friedman LS, Friedman MI, Munoz SJ, Deems DA, Maddrey WC 1994 Relationship between liver biochemical tests and dietary intake in patients with liver disease. J. Clin. Gastroenterol. 18: 304-308.
Degos F, Degott C, Erlinger S 1980 Ineffectiveness of corticosteroids in cholestatic forms of chronic active hepatitis. Gastroenterol. Clin. Biol. 4: 246-250.
Delacroix DL, Reynaert M, Pauwels S, Geubel AP, Vaerman JP 1982 High serum levels of secretory IgA in liver disease: possible liver origin of the circulating secretory component. Dig. Dis. Sci. 27: 333-340.
Delle Monache M, Salvio A, Fiocca F, Basoli A, Ricci GL 1992 Primary sclerosing cholangitis: an analysis of 37 retrospective cases. Ital. J. Gastroenterol. 24: 485-488.
Der G, Love T, Schreck J, Horn M 2005 Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16. *
Descamps V 2006 Efalizumab. Ann. Dermatol. Venereol. 133: 666-678.
Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK 2007 The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 27: 1402-1408. *
Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A 1996 Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int. J. Gynaecol. Obstet. 52: 133-140.
Diaz FJ, Davalos MM, Roman VR, Bustios SC, Zumaeta VE 2004 Hepatotoxicity and pancreatitis associated with gold salts: case report. Rev. Gastroenterol. Peru 24: 353-356.
Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A 1999 Evolution of osteopenia in inflammatory bowel disease. Am. J. Gastroenterol. 94: 1292-1297. *
Ding Y, Zhao L, Mei H, Zhang SL, Huang ZH, Duan YY, Ye P 2008 Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. 590: 377-386.
Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H 1999 Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98.
Doganci T, Bozkurt S 2004 Celiac disease with various presentations. Pediatr. Int. 46: 693-696.
Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K 2004 Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J. Gastroenterol. 10: 894-898. *
Domar U, Danielsson A, Hirano K, Stigbrand T 1988 Alkaline phosphatase isozymes in non-malignant intestinal and hepatic diseases. Scand. J. Gastroenterol. 23: 793-800.
Dominick HC, Husen NV, Hosemann R, Gerlach U 1975 Isoenzymes of alkaline phosphatase in the serum of patients with cystic fibrosis. Z. Kinderheilkd. 119: 261-267.
Dotan I, Hallak A, Arber N, Santo M, Alexandrowitz A, Knaani Y, Hershkoviz R, Brazowski E, Halpern Z 2001 Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig. Dis. Sci. 46: 2239-2244. *
Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D 2000 Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 699-704. *
Drivdal M, Trydal T, Hagve TA, Bergstad I, Aagenaes O 2006 Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome). Scand. J. Gastroenterol. 41: 465-471. *
Duan RD 2006 Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim. Biophys. Acta 1761: 281-291. *
Duan RD, Cheng Y, Tauschel HD, Nilsson A 1998 Effects of ursodeoxycholate and other bile salts on levels of rat intestinal alkaline sphingomyelinase: a potential implication in tumorigenesis. Dig. Dis. Sci. 43: 26-32. *
Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C 1995 Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J. Hepatol. 23: 674-680. *
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF 2003 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125: 298-303. *
Dueland S, Reichen J, Everson GT, Davis RA 1991 Regulation of cholesterol and bile acid homoeostasis in bile-obstructed rats. Biochem. J. 280: 373-377.
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46: 2027-2049. *
Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB 2000 Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46: 2050-2068. *
Dumonceau JM, Deviere J, Delhaye M, Baize M, Cremer M 1998 Plastic and metal stents for postoperative benign bile duct strictures: the best and the worst. Gastrointest. Endosc. 47: 8-17. *
Ebbeson RL, Schreiber RA 2004 Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin. Gastroenterol. Hepatol. 2: 935-940. *
Ebert EC, Nagar M 2008 Gastrointestinal manifestations of amyloidosis. Am. J. Gastroenterol. 103: 776-787. *
Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J 2005 Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol. Immunotoxicol. 27: 77-83.
El-Beshbishy HA 2008 Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. Jun 20 [Epub ahead of print].
Elisaf M 2002 Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18: 269-276.
Ellis G, Worthy E, Goldberg DM 1979 Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. Clin. Biochem. 12: 142-145.
Engle MJ, Mahmood A, Alpers DH 1995 Two rat intestinal alkaline phosphatase isoforms with different carboxyl-terminal peptides are both membrane-bound by a glycan phosphatidylinositol linkage. J. Biol. Chem. 270: 11935-11940. *
Enns R, Eloubeidi MA, Mergener K, Jowell PS, Branch MS, Baillie J 2003 Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography. Can. J. Gastroenterol. 17: 243-248.
Epstein E, Kiechle FL, Zak B 1984 Use of alkaline phosphatase isoenzyme analysis in the evaluation of cholestatic liver disease. Ann. Clin. Lab. Sci. 14: 292-297.
Epstein MP, Kaplan MM 2004 A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig. Dis. Sci. 49: 1-4. *
Erices A, Conget P, Rojas C, Minguell JJ 2002 Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp. Cell Res. 280: 24-32. *
Faa G, Van Eyken P, Demelia L, Vallebona E, Costa V, Desmet VJ 1991 Idiopathic adulthood ductopenia presenting with chronic recurrent cholestasis. A case report. J. Hepatol. 12: 14-20.
Fagundes ED, Roquete ML, Penna FJ, Reis FJ, Duque CG 2002 Diagnostic screening of liver disease in cystic fibrosis. J. Pediatr. (Rio. J.) 78: 389-396.
Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P 2004 Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40: 1379-1386. *
Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R 1991 Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 100: 1710-1717.
Farver DK, Lavin MN 1999 Quinine-induced hepatotoxicity. Ann. Pharmacother. 33: 32-34.
Faust D, Menge F, Armbruster FP, Lembcke B, Stein J 2003 Increased serum bone sialoprotein concentrations in patients with Crohn's disease. Z. Gastroenterol. 41: 243-247.
Fazle Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M 2005 Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J. Gastroenterol. 40: 157-163. *
Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P 2003 Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 38: 210-217. *
Ferguson A, Watson WC, Maxwell JD, Fell GS 1968 Alkaline phosphatase levels in normal and diseased small bowel. Gut 9: 96-98. *
Fernandez-Banares F, Mingorance MD, Esteve M, Cabre E, Lachica M, Abad-Lacruz A, Gil A, Humbert P, Boix J, Gassull MA 1990 Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status. Am. J. Gastroenterol. 85: 1584-1589.
Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB 2004 Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 97: 407-412. *
Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M 2006 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130: 465-481. *
Filipovic B, Opric M, Milicic A, Paranos S 2002 Primary biliary cirrhosis. Srp. Arh. Celok. Lek. 130: 213-216.
Findlay DM, Chehade M, Tsangari H, Neale S, Hay S, Hopwood B, Panach S, O'Loughlin P, Fazzalari NL 2008 Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males. Arthritis Res. Ther. 10: R2. *
Fiore CE, Pennisi P, Ferro G, Ximenes B, Privitelli L, Mangiafico RA, Santoro F, Parisi N, Lombardo T 2006 Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm. Metab. Res. 38: 417-422.
Firmin D, Roguedas AM, Lemasson G, Abgrall JF, Misery L 2008 Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects. Dermatology 217: 203-206.
Firouzi F, Rashidi M, Hashemi S, Kangavari M, Bahari A, Daryani NE, Emam MM, Naderi N, Shalmani HM, Farnood A, Zali M 2007 A decision tree-based approach for determining low bone mineral density in inflammatory bowel disease using WEKA software. Eur. J. Gastroenterol. Hepatol. 19: 1075-1081.
Fisher L, Fisher A 2007 Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin. Gastroenterol. Hepatol. 5: 513-520.
Fitch P, Bennett B, Booth NA, Croll A, Ewen SW 1994 Distribution of plasminogen activator inhibitor in normal liver, cirrhotic liver, and liver with metastases. J. Clin. Pathol. 47: 218-221. *
Flisiak R, Pelszynska M, Prokopowicz D, Rogalska M, Grygoruk U 2005 High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J. Gastroenterol. 11: 5706-5709. *
Floreani A, Baragiotta A, Martines D, Naccarato R, D'odorico A 2000 Plasma antioxidant levels in chronic cholestatic liver diseases. Aliment. Pharmacol. Ther. 14: 353-358. *
Floreani A, Paternoster D, Melis A, Grella PV 1996 S-Adenosylmethionine versus ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy: preliminary results of a controlled trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 67: 109-113.
Floreani A, Zappala F, Mazzetto M, Naccarato R, Plebani M, Chiaramonte M 1994 Different response to ursodeoxycholic acid (UDCA) in primary biliary cirrhosis according to severity of disease. Dig. Dis. Sci. 39: 9-14.
Fontana RJ, Kleiner DE, Bilonick R, Terrault N, Afdhal N, Belle SH, Jeffers LJ, Ramcharran D, Ghany MG, Hoofnagle JH 2006 Modeling hepatic fibrosis in African American and Caucasian American patients with chronic hepatitis C virus infection. Hepatology 44: 925-935. *
Forbes A, Blanshard C, Gazzard B 1993 Natural history of AIDS related sclerosing cholangitis: a study of 20 cases. Gut 34: 116-121. *
Foreman JE, Blizard DA, Gerhard G, Mack HA, Lang DH, Van Nimwegen KL, Vogler GP, Stout JT, Shihabi ZK, Griffith JW, Lakoski JM, McClearn GE, Vandenbergh DJ 2005 Serum alkaline phosphatase activity is regulated by a chromosomal region containing the alkaline phosphatase 2 (Akp2) gene in C57BL/6J and DBA/2J mice. Physiol. Genomics 23: 295-303. *
Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E 2004 Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 20: 607-614. *
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Frederiks WM, Van Noorden CJ, Aronson DC, Marx F, Bosch KS, Jonges GN, Vogels IM, James J 1990 Quantitative changes in acid phosphatase, alkaline phosphatase and 5'-nucleotidase activity in rat liver after experimentally induced cholestasis. Liver 10: 158-166.
Frediani B, Rossini M, Adami S, Bianchi G, Di Munno O, Sinigaglia L, Antonelli M, Minisola G 2006 Study of vitamin D status of rheumatoid arthritis patients. Rationale and design of a cross-sectional study by the osteoporosis and metabolic bone diseases study group of the Italian Society of Rheumatology (SIR). Reumatismo 58: 314-318.
Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C 1993 Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig. Dis. Sci. 38: 1291-1296.
Frezza M 1993 A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis. Ann. Ital. Med. Int. 8 Suppl.: 48S-51S.
Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C 1990 Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study. Gastroenterology 99: 211-215.
Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB 1992 Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629.
Fu Y, Zheng S, Lin J, Ryerse J, Chen A 2008 Curcumin protects the rat liver from CCl4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 73: 399-409. *
Fujiyama N, Shitara Y, Ito K, Masubuchi Y, Horie T 2007 Down-regulation of hepatic transporters for BSP in rats with indomethacin-induced intestinal injury. Biol. Pharm. Bull. 30: 556-561. *
Fukui K, Hada T, Imanishi H, Liu W, Iwasaki A, Hirano K, Higashino K 1997 The tumor-derived fetal-intestinal alkaline phosphatase cDNA is identical in sequence to the adult intestinal alkaline phosphatase isozyme gene. Clin. Chim. Acta 265: 57-63. *
Fukuo Y, Kitami T, Nomoto T, Terashi A 1996 A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nippon Ika Daigaku Zasshi 63: 424-430.
Fukushima K, Sasaki I, Takahashi K, Naito H, Ogawa H, Sato S, Matsuno S 1998 Lipopolysaccharide exhibits synergistic enhancement of butyrate-induced and retinoic acid-mediated alkaline phosphatase activity on small intestinal epithelial cell line, IEC-6. Digestion 59: 683-688.
Funke S, Morava E, Czako M, Vida G, Ertl T, Kosztolanyi G 2006 Influence of genetic polymorphisms on bone disease of preterm infants. Pediatr. Res. 60: 607-612. *
Furuya T, Tateishi M, Nishinarita M, Kashiwazaki S 1995 Primary biliary cirrhosis in patients with Sjogren's syndrome. Nippon Rinsho 53: 2536-2539.
Fusai G, Dhaliwal P, Rolando N, Sabin CA, Patch D, Davidson BR, Burroughs AK, Rolles K 2006 Incidence and risk factors for the development of prolonged and severe intrahepatic cholestasis after liver transplantation. Liver Transpl. 12: 1626-1633. *
Gabriel SE, Conn DL, Luthra H 1990 Rifampin therapy in rheumatoid arthritis. J. Rheumatol. 17: 163-166.
Gajewska J, Ambroszkiewicz J, Hozyasz KK 2005 The impairement of bone formation and resorption in 25-year-old man with neglected celiac disease. Wiad. Lek. 58: 338-341.
Gajewska J, Ambroszkiewicz J, Hozyasz KK 2005 Biochemical markers of bone turnover in children with celiac disease on gluten-free diet. Med. Wieku. Rozwoj. IX: 675-683.
Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A 1990 Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 12: 486-491.
Ganotakis E, Tsimihodimos V, Bairaktari E, Rizos E, Athyros V, Seferiades C, Elisaf M 2002 Effects of various fibrates on serum alkaline phosphatase activity. Atherosclerosis 165: 187-188.
Gao X, Sedgwick T, Shi YB, Evans T 1998 Distinct functions are implicated for the GATA-4, -5, and -6 transcription factors in the regulation of intestine epithelial cell differentiation. Mol. Cell Biol. 18: 2901-2911. *
Garcia Ruiz P, Canora Lebrato J, Diez Ruiz A, Fuchs D, Wachter H 2004 Soluble interleukin-2 and tumor necrosis factor receptor in liver cirrhosis. Relationship with clinical severity and prognosis. Med. Clin. (Barc.) 122: 441-443.
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J 1991 The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315.
Garduno-Siciliano L, Labarrios F, Tamariz J, Moreno MG, Chamorro G, Muriel P 2007 Effect of alpha-asarone and a derivative on lipids, bile flow and Na(+)/K(+)-ATPase in ethinyl estradiol-induced cholestasis in the rat. Fundam. Clin. Pharmacol. 21: 81-88.
Geddes K, Philpott DJ 2008 A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135: 8-12. *
Germenis AE, Yiannaki EE, Zachou K, Roka V, Barbanis S, Liaskos C, Adam K, Kapsoritakis AN, Potamianos S, Dalekos GN 2005 Prevalence and clinical significance of immunoglobulin A antibodies against tissue transglutaminase in patients with diverse chronic liver diseases. Clin. Diagn. Lab. Immunol. 12: 941-948. *
Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ 2004 Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J. Hepatol. 41: 1017-1025. *
Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I 2004 Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report. Rom. J. Gastroenterol. 13: 33-38.
Ghosh AK, Mullins JI 1995 cDNA encoding a functional feline liver/bone/kidney-type alkaline phosphatase. Arch. Biochem. Biophys. 322: 240-249. *
Gianni M, Studer M, Carpani G, Terao M, Garattini E 1991 Retinoic acid induces liver/bone/kidney-type alkaline phosphatase gene expression in F9 teratocarcinoma cells. Biochem. J. 274: 673-678. *
Gianni M, Terao M, Sozzani S, Garattini E 1993 Retinoic acid and cyclic AMP synergistically induce the expression of liver/bone/kidney-type alkaline phosphatase gene in L929 fibroblastic cells. Biochem. J. 29: 67-77. *
Gianni M, Zanotta S, Terao M, Garattini S, Garattini E 1993 Effects of synthetic retinoids and retinoic acid isomers on the expression of alkaline phosphatase in F9 teratocarcinoma cells. Biochem. Biophys. Res. Commun. 196: 252-259. *
Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R 2000 Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int. J. Biol. Markers 15: 226-230.
Gilger MA, Gann ME, Opekun AR, Gleason WA Jr 2000 Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 31: 136-141. *
Gilman J, Shanahan F, Cashman KD 2006 Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1007-1016. *
Gindro T, Arrigoni A, Martinasso G, Rosina F, Perardi S, Cappello N, Benedetti P, Actis GC, Verme G, Rizzetto M 1997 Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur. J. Gastroenterol. Hepatol. 9: 1155-1159.
Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J 2007 Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114. *
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN 2003 Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin. Exp. Rheumatol. 21: 333-339.
Gogolauri M, Antelava N 2005 Effect of heptral and folic acid on the hepatic functions during toxic hepatitis. Georgian Med. News 6: 57-60.
Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A 1999 Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324. *
Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, Meyer zum Buschenfelde KH 1996 Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol. 24: 699-705. *
Goldberg DM, Spooner RJ, Ellis G, Ward AM 1979 Biochemical features of intrahepatic cholestasis. Am. J. Clin. Pathol. 71: 557-563.
Goldberg RF, Austen WG Jr, Zhang X, Munene G, Mostafa G, Biswas S, McCormack M, Eberlin KR, Nguyen JT, Tatlidede HS, Warren HS, Narisawa S, Millan JL, Hodin RA 2008 Intestinal alkaline phosphatase is a gut mucosal defense factor maintained by enteral nutrition. Proc. Natl. Acad. Sci. U.S.A. 105: 3551-3556. *
Gollan JL 2003 Morbus Wilson. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper�s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 91-92. October 17 - 19. *
Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD 2003 Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30.
Gong Y, Gluud C 2005 Methotrexate for primary biliary cirrhosis. Cochrane Database Syst. Rev. 3: CD004385. *
Gonzalez M, Ribalta J, Reyes H, Klinger J, Maggiolo P, Varleta P, Hernandez I, Delgado M, Donoso S 1990 Primary biliary cirrhosis. The clinical experience in 31 patients. Rev. Med. Chil. 118: 1350-1354.
Goseki-Sone M, Oida S, Iimura T, Yamamoto A, Matsumoto HN, Omi N, Takeda K, Maruoka Y, Ezawa I, Sasaki S 1996 Expression of mRNA encoding intestinal type alkaline phosphatase in rat liver and its increase by fat-feeding. Liver 16: 358-364.
Gracey M, Houghton M, Thomas J 1975 Deoxycholate depresses small-intestinal enzyme activity. Gut 16: 53-56. *
Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, Blesa A, Montejo JC, Garcia de Lorenzo A, Mesejo A 2007 Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 11: R10. *
Green RM, Flamm S 2002 AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 123: 1367-1384. *
Gregorio GV, Ball CS, Mowat AP, Mieli-Vergani G 1993 Effect of rifampicin in the treatment of pruritus in hepatic cholestasis. Arch. Dis. Child. 69: 141-143.
Gremse DA, Bucuvalas JC, Bongiovanni GL 1989 Papillary stenosis and sclerosing cholangitis in an immunodeficient child. Gastroenterology 96: 1600-1603.
Gresser U 2001 Amoxicillin-clavulanic acid therapy may be associated with severe side effects - review of the literature. Eur. J. Med. Res. 6: 139-149. *
Griel AE, Kris-Etherton PM, Hilpert KF, Zhao G, West SG, Corwin RL 2007 An increase in dietary n-3 fatty acids decreases a marker of bone resorption in humans. Nutr. J. 6: 2. *
Griga T, Tromm A, Muller KM, May B 2000 Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases. Eur. J. Gastroenterol. Hepatol. 12: 559-564.
Grodzicki M, Pawlak J, Chrzanowska A, Porembska Z, Krawczyk M 2004 Arginase activity concentration marking in monitoring of hepatocytes function after orthotopic liver transplantation - preliminary report. Ann. Transplant. 9: 54-57.
Groen AK, Van Wijland MJ, Frederiks WM, Smit JJ, Schinkel AH, Oude Elferink RP 1995 Regulation of protein secretion into bile: studies in mice with a disrupted mdr2 p-glycoprotein gene. Gastroenterology 109: 1997-2006. *
Gross JB Jr, Kumar N 2003 Simultaneous occurrence of PSC and MS in a patient. Dig. Dis. Sci. 48: 1397. *
Gruchy SE, Fardy JM 2003 A meta-analysis of ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 98: S90. *
Grune S, Mullhaupt B, Moradpour D, Munch R, Siegenthaler-Zuber G, Siegenthaler W 1991 Primary sclerosing cholangitis. Dtsch. Med. Wochenschr. 116: 1095-1100.
Grungreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, Klauck S, Diete U 1988 Clinical studies on zinc in chronic liver diseases. Z. Gastroenterol. 26: 409-415.
Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, Peris P, Rodes J 2005 Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. J. Hepatol. 42: 573-577. *
Guattery JM, Faloon WW 1987 Effect of estradiol upon serum enzymes in primary biliary cirrhosis. Hepatology 7: 737-742.
Guichelaar MM, Kendall R, Malinchoc M, Hay JE 2006 Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 12: 1390-1402. *
Gullberg E, Leonard M, Karlsson J, Hopkins AM, Brayden D, Baird AW, Artursson P 2000 Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279: 808-813. *
Gunsar C, Melek M, Karaca I, Sencan A, Mir E, Ortac R, Canan O 2002 The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study. Hepatogastroenterology 49: 497-500.
Gunsar F, Akarca US, Ersoz G, Karasu Z, Yuce G, Batur Y 2002 Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology 49: 1195-1200.
Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK 2001 Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J. Gastroenterol. Hepatol. 16: 1144-1148. *
Guslandi M 1990 Treatment of chronic liver disease with ursodeoxycholic acid. J. Int. Med. Res. 18: 497-505.
Guy JE, Qian P, Lowell JA, Peters MG 2005 Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 11: 1252-1257. *
Gyamfi MA, Damjanov I, French S, Wan YJ 2008 The pathogenesis of ethanol versus methionine and choline deficient diet-induced liver injury. Biochem. Pharmacol. 75: 981-995. *
Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M 2003 Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 52: 653-658. *
Hampel R, Weber S, Rose HJ, Meng W, Nilius R 1981 Alkaline phosphatase isoenzymes and hyperthyroidism. Z. Gesamte. Inn. Med. 36: 909-913.
Hanik L, Eriksson S 1977 Presymptomatic primary biliary cirrhosis. Acta Med. Scand. 202: 277-281.
Hanna AN, Waldman WJ, Lott JA, Koesters SC, Hughes AM, Thornton DJ 1997 Increased alkaline phosphatase isoforms in autoimmune diseases. Clin. Chem. 43: 1357-1364. *
Hansen GH, Niels-Christiansen LL, Immerdal L, Nystrom BT, Danielsen EM 2007 Intestinal alkaline phosphatase: selective endocytosis from the enterocyte brush border during fat absorption. Am. J. Physiol. Gastrointest. Liver Physiol. 293: G1325-G1332. *
Harada T, Koyama I, Kasahara T, Alpers DH, Komoda T 2003 Heat shock induces intestinal-type alkaline phosphatase in rat IEC-18 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G255-G262. *
Harada T, Koyama I, Matsunaga T, Kikuno A, Kasahara T, Hassimoto M, Alpers DH, Komoda T 2005 Characterization of structural and catalytic differences in rat intestinal alkaline phosphatase isozymes. FEBS J. 272: 2477-2486. *
Haratake J, Kasai T, Makino H 2002 Diffuse mucosal carcinoma of intrahepatic and extrahepatic bile ducts including gallbladder. Pathol. Int. 52: 784-788. *
Harding G, McKenna R, Minuk G 2001 The immune response to alkaline phosphatase and other immunogens in patients with primary biliary cirrhosis. Hepatogastroenterology 48: 66-70.
Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am. J. Gastroenterol. 96: 1558-1562. *
Harrison J, McKiernan J, Neuberger JM 1997 A prospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl. Int. 10: 369-374.
Hasegawa M, Ide M, Fujita T, Takenaka S 2008 Urinary metabolic fingerprinting for alpha-naphthylisothiocyanate-induced intrahepatic cholestasis in rats using Fourier transform-ion cyclotron resonance mass spectrometry. Toxicol. Pathol. Sep 5 [Epub ahead of print]. *
Hashimoto E, Ideta M, Taniai M, Watanabe U, Okuda H, Nagasako K, Hisamitsu T, Obata H 1993 Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. J. Gastroenterol. Hepatol. 8: 146-149.
Hatoff DE, Hardison WG 1981 Bile acids modify alkaline phosphatase induction and bile secretion pressure after bile duct obstruction in the rat. Gastroenterology 80: 666-672.
Haugen HF, Skrede S 1976 Nucleotide pyrophosphatase and phosphodiesterase I. Demonstration of activity in normal serum, and an increase in cholestatic liver disease. Scand. J. Gastroenterol. 11: 121-127.
Hawrylak K, Stinson RA 1988 The solubilization of tetrameric alkaline phosphatase from human liver and its conversion into various forms by phosphatidylinositol phospholipase C or proteolysis. J. Biol. Chem. 263: 14368-14373. *
Hazama H, Omagari K, Masuda J, Kinoshita H, Ohba K, Sakimura K, Matsuo I, Isomoto H, Murase K, Murata I, Kohno S 2000 Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis. J. Clin. Lab. Anal. 14: 208-213. *
Heath JK, Suva LJ, Yoon K, Kiledjian M, Martin TJ, Rodan GA 1992 Retinoic acid stimulates transcriptional activity from the alkaline phosphatase promoter in the immortalized rat calvarial cell line, RCT-1. Mol. Endocrinol. 6: 636-646. *
Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al 1994 The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156.
Heathcote J 2004 Diagnosis of primary biliary liver diseases, overlap syndromes and changing diagnosis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 55. *
Heathcote J 2003 Overlap syndromes - outlier syndromes and changing diagnoses. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 39-41. October 15-16. *
Heathcote J, Ross A, Sherlock S 1976 A prospective controlled trial of azathioprine in primary biliary cirrhosis. Gastroenterology 70: 656-660.
Heikkinen J, Maentausta O, Ylostalo P, Janne O 1982 Serum bile acid levels in intrahepatic cholestasis of pregnancy during treatment with phenobarbital or cholestyramine. Eur. J. Obstet. Gynecol. Reprod. Biol. 14: 153-162.
Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D 1999 Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407. *
Henthorn PS, Raducha M, Edwards YH, Weiss MJ, Slaughter C, Lafferty MA, Harris H 1987 Nucleotide and amino acid sequences of human intestinal alkaline phosphatase: close homology to placental alkaline phosphatase. Proc. Natl. Acad. Sci. U.S.A. 84: 1234-1238. *
Henthorn PS, Raducha M, Kadesch T, Weiss MJ, Harris H 1988 Sequence and characterization of the human intestinal alkaline phosphatase gene. J. Biol. Chem. 263: 12011-12019. *
Herrine SK 2003 Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Herszenyi L, Szalay L, Schaff Z, Gergely P, Feher J 1993 Ursodeoxycholic acid therapy in biliary cirrhosis. Orv. Hetil. 134: 2085-2089.
Heubi JE, Wiechmann DA, Creutzinger V, Setchell KD, Squires R Jr, Couser R, Rhodes P 2002 Tauroursodeoxycholic acid (TUDCA) in the prevention of total parenteral nutrition-associated liver disease. J. Pediatr. 141: 237-242. *
Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, Louvet H, Fremond L, Geoffroy P, Schmit JL, Cadiot G, Thiefin G 2007 Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol. Clin. Biol. 31: 17-25. *
Higuchi T, Hishida N, Isomura T, Takeshima H, Hayashi H 1992 The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids. Gastroenterol. Jpn. 27: 222-229.
Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, Lee SD 2004 Fenofibrate-induced acute cholestatic hepatitis. J. Chin. Med. Assoc. 67: 245-247. *
Hodin RA, Chamberlain SM, Upton MP 1992 Thyroid hormone differentially regulates rat intestinal brush border enzyme gene expression. Gastroenterology 103: 1529-1536.
Hodin RA, Shei A, Morin M, Meng S 1996 Thyroid hormone and the gut: selective transcriptional activation of a villus-enterocyte marker. Surgery 120: 138-143.
Hoekstra H, Porte RJ, Tian Y, Jochum W, Stieger B, Moritz W, Slooff MJ, Graf R, Clavien PA 2006 Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice. Hepatology 43: 1022-1031. *
Hoensch HP, Balzer K, Dylewizc P, Kirch W, Goebell H, Ohnhaus EE 1985 Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur. J. Clin. Pharmacol. 28: 475-477.
Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G 2002 Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J. Gastroenterol. Hepatol. 17: 308-315. *
Holt KM, Miyai K, Chojkier M 1986 Asymptomatic primary biliary cirrhosis in an old man. J. Clin. Gastroenterol. 8: 203-206.
Homburger HA, Casey M, Jacob GL, Klee GG 1984 Measurement of secretory IgA in serum by radioimmunoassay in patients with chronic nonalcoholic liver disease or carcinoma. Am. J. Clin. Pathol. 81: 569-574.
Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, Kate FT, van Deventer SJ 2008 A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. J. Clin. Gastroenterol. 42: 522-526.
Honda M, Kawai H, Shirota Y, Yamashita T, Takamura T, Kaneko S 2005 cDNA microarray analysis of autoimmune hepatitis, primary biliary cirrhosis and consecutive disease manifestation. J. Autoimmun. 25: 133-140.
Honorati MC, Cattini L, Facchini A 2007 VEGF production by osteoarthritic chondrocytes cultured in micromass and stimulated by IL-17 and TNF-alpha. Connect. Tissue Res. 48: 239-245.
Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG, Minuk GY, Dusheiko GM, Campbell G, et al 1986 Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 91: 1327-1334.
Horiguchi N, Ishac EJ, Gao B 2007 Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol 41: 271-280.
Horvat-Karajz K, Csepregi A, Nemesanszky E, Tulassay Z, Selmeci L, Szalay F 2000 Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis. Orv. Hetil. 141: 963-965.
Huang MJ, Liaw YF 1995 Clinical associations between thyroid and liver diseases. J. Gastroenterol. Hepatol. 10: 344-350.
Hung SH, Yeh CH, Huang HT, Wu P, Ho ML, Chen CH, Wang C, Chao D, Wang GJ 2008 Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-gamma pathway. Life Sci. 82: 561-569. *
Hunt JB, Sayer JM, Jacyna M, Crofton M, Summerfield JA 1993 Combined percutaneous transhepatic and endoscopic placement of biliary stents. Surg. Oncol. 2: 293-298.
Hussaini SH, Farrington EA 2007 Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6: 673-684.
Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ 1993 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223.
Iivonen MK, Mattila JJ, Nordback IH, Matikainen MJ 2000 Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy. A randomized prospective study. Scand. J. Gastroenterol. 35: 679-685. *
Ikeda T, Sato C, Noguchi O, Kobayashi F, Tozuka S, Sakamoto S, Marumo F 1996 Improvement of peripheral blood lymphocyte subsets in primary biliary cirrhosis after ursodeoxycholic acid therapy. J. Gastroenterol. Hepatol. 11: 366-372.
Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, Sato C 1996 Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J. Hepatol. 24: 88-94. *
Ilan Y, Shouval D 1992 Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687.
Imauchi Y, Jeunemaitre X, Boussion M, Ferrary E, Sterkers O, Grayeli AB 2008 Relation between renin-angiotensin-aldosterone system and otosclerosis: a genetic association and in vitro study. Otol. Neurotol. 29: 295-301.
Inoue Y, Shimojo N, Suzuki S, Arima T, Tomiita M, Minagawa M, Kohno Y 2008 Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin. Rheumatol. 27: 909-912. *
Isabel Fiel M, Thung SN, Hytiroglou P, Emre S, Schiano TD 2007 Liver failure and need for liver transplantation in patients with advanced hepatoportal sclerosis. Am. J. Surg. Pathol. 31: 607-614.
Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, Tsuchiya K, Hamano K, Asahina Y, Kurosaki M, Uchihara M, Miyake S 2004 Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol. Res. 29: 216-222.
Ito M, Kojima T, Miyata M, Saka M, Kokubun M, Ohira H, Ishikawa H, Kuroda M, Sato Y, Takagi T, et al 1995 Primary biliary cirrhosis (PBC)-CREST (calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly and telangiectasia) overlap syndrome complicated by Sjogren's syndrome and arthritis. Intern. Med. 34: 451-454. *
Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S 1999 Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16: 12-18.
Jacobsen MB, Fausa O, Elgjo K, Schrumpf E 1990 Hepatic lesions in adult coeliac disease. Scand. J. Gastroenterol. 25: 656-662.
Jansen PL, Cuypers HT, Peters WH 1984 Quantitation of bilirubin conjugates with high-performance liquid chromatography in patients with low total serum bilirubin levels. Eur. J. Clin. Invest. 14: 295-300.
Jansen PL, Peters WH, Janssens AR 1986 Clinical value of serum bilirubin subfractionation by high-performance liquid chromatography and conventional methods in patients with primary biliary cirrhosis. J. Hepatol. 2: 485-494.
Javid PJ, Collier S, Richardson D, Iglesias J, Gura K, Lo C, Kim HB, Duggan CP, Jaksic T 2005 The role of enteral nutrition in the reversal of parenteral nutrition-associated liver dysfunction in infants. J. Pediatr. Surg. 40: 1015-1018.
Javitt NB 1989 Cholestatic liver disease and its management. Baillieres Clin. Gastroenterol. 3: 423-430.
Jiang XH, Zhong RQ, Fang XY, An F, Hu Y, Wang XP, Kong XT 2006 Establishment of a mouse model of primary biliary cirrhosis by AMA M2 autoantigen injection. Zhonghua Gan Zang Bing Za Zhi 14: 202-204.
Johnson K, Kotiesh A, Boitnott JK, Torbenson M 2007 Histology of symptomatic acute hepatitis C infection in immunocompetent adults. Am. J. Surg. Pathol. 31: 1754-1758.
Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA 1999 Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 1165-1169.
Jorge A, Findor J, Esley C, Bruch E 1988 Primary sclerosing cholangitis. Z. Gastroenterol. 26: 322-330.
Jorge AD, Esley C 1985 Primary sclerosing cholangitis. Endoscopy 17: 11-14.
Jorgensen RA, Dickson ER, Hofmann AF, Rossi SS, Lindor KD 1995 Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 36: 935-938. *
Josephine A, Veena CK, Amudha G, Preetha SP, Varalakshmi P 2006 Evaluating the effect of sulphated polysaccharides on cyclosporine A induced oxidative renal injury. Mol. Cell. Biochem. 287: 101-108. *
Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ 2002 Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid. Hepatology 35: 409-413. *
Jun SY, Kim JS, Yu E 2002 Primary sclerosing cholangitis - a report of two liver explants. Korean J. Pathol. 36: 420-424. *
Kaaja RJ, Kontula KK, Raiha A, Laatikainen T 1994 Treatment of cholestasis of pregnancy with peroral activated charcoal. A preliminary study. Scand. J. Gastroenterol. 29: 178-181.
Kajander EO, Ciftcioglu N 1998 Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc. Natl. Acad. Sci. U.S.A. 95: 8274-8279. *
Kakar S, Batts KP, Poterucha JJ, Burgart LJ 2004 Histologic changes mimicking biliary disease in liver biopsies with venous outflow impairment. Mod. Pathol. 17: 874-878. *
Kakumu S, Yoshioka K, Tsutsumi Y, Wakita T, Arao M 1990 Production of tumor necrosis factor, interleukin 1, and interferon-gamma by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Clin. Immunol. Immunopathol. 56: 54-65.
Kaler B, Karram T, Morgan WA, Bach PH, Yousef IM, Bomzon A 2004 Are bile acids involved in the renal dysfunction of obstructive jaundice? An experimental study in bile duct ligated rats. Ren. Fail. 26: 507-516.
Kamitani H, Ikawa H, Hsi LC, Watanabe T, DuBois RN, Eling TE 1999 Regulation of 12-lipoxygenase in rat intestinal epithelial cells during differentiation and apoptosis induced by sodium butyrate. Arch. Biochem. Biophys. 368: 45-55. *
Kampa IS, Jarzabek J, Clain J 1976 The use of gamma-glutamyl transpeptidase in differentiating liver from bone isoenzymes of alkaline phosphatase. Clin. Biochem. 9: 234-236.
Kananathan R, Suresh RL, Merican I 2002 Primary biliary cirrhosis at Hospital Kuala Lumpur: a study of 17 cases seen between 1992 and 1999. Med. J. Malaysia 57: 56-60.
Kanda T, Yokosuka O, Imazeki F, Saisho H 2003 Bezafibrate treatment: a new medical approach for PBC patients? J. Gastroenterol. 38: 573-578. *
Kang JS, Wanibuchi H, Morimura K, Wongpoomchai R, Chusiri Y, Gonzalez FJ, Fukushima S 2008 Role of CYP2E1 in thioacetamide-induced mouse hepatotoxicity. Toxicol. Appl. Pharmacol. 228: 295-300. *
Kanno N, LeSage G, Glaser S, Alpini G 2001 Regulation of cholangiocyte bicarbonate secretion. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G612-G625. *
Kao JH, Lai MY, Lin JT, Yang PM, Sheu JC, Chen DS, Sung JL, Wang TH 1991 Therapeutic effect of ursodeoxycholic acid on early-stage primary biliary cirrhosis. J. Formos. Med. Assoc. 90: 970-974.
Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta GH, Glick KA, Eagen KA 1986 A prospective trial of colchicine for primary biliary cirrhosis. N. Engl. J. Med. 315: 1448-1454.
Kaplan MM, Cheng S, Price LL, Bonis PAL 2004 A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results. Hepatology 39: 915-923. *
Kaplan MM, Knox TA 1991 Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 101: 1332-1338.
Kaplan MM, Ohkubo A, Quaroni EG, Sze-Tu D 1983 Increased synthesis of rat liver alkaline phosphatase by bile duct ligation. Hepatology 3: 368-376.
Kaplan MM, Schmid C, Provenzale D, Sharma A, Dickstein G, McKusick A 1999 A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis. Gastroenterology 117: 1173-1180. *
Karvonen J, Kairisto V, Gronroos JM 2006 Stone or stricture as a cause of extrahepatic cholestasis - do liver function tests predict the diagnosis? Clin. Chem. Lab. Med. 44: 1453-1456. *
Kaur J, Madan S, Hamid A, Singla A, Mahmood A 2007 Intestinal alkaline phosphatase secretion in oil-fed rats. Dig. Dis. Sci. 52: 665-670. *
Kay M, Wyllie R, Michener W, Caulfield M, Steffen R 1993 Associated ulcerative colitis, sclerosing cholangitis, and insulin-dependent diabetes mellitus. Cleve. Clin. J. Med. 60: 473-478.
Keaveny AP, Karasik MS 1998 Hepatobiliary and pancreatic infections in AIDS: Part II. AIDS Patient Care STDS. 12: 451-456.
Kenny RP, Czaja AJ, Ludwig J, Dickson ER 1986 Frequency and significance of antimitochondrial antibodies in severe chronic active hepatitis. Dig. Dis. Sci. 31: 705-711.
Khan KN, Tsutsumi T, Nakata K, Kato Y 1999 Sodium butyrate induces alkaline phosphatase gene expression in human hepatoma cells. J. Gastroenterol. Hepatol. 14: 156-162. *
Khan KN, Tsutsumi T, Nakata K, Nakao K, Kato Y, Nagataki S 1998 Regulation of alkaline phosphatase gene expression in human hepatoma cells by bile acids. J. Gastroenterol. Hepatol. 13: 643-650.
Kihn L, Dinwoodie A, Stinson RA 1991 High-molecular-weight alkaline phosphatase in serum has properties similar to the enzyme in plasma membranes of the liver. Am. J. Clin. Pathol. 96: 470-478.
Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, Han YS, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R 2004 Autoimmune cholangitis in a patient with thymoma. J. Gastroenterol. Hepatol. 19: 1324-1327. *
Kim JH, Meng S, Shei A, Hodin RA 1999 A novel Sp1-related cis element involved in intestinal alkaline phosphatase gene transcription. Am. J. Physiol. 276: G800-G807. *
Kim YC, Jung YS, Kim SK 2005 Effect of betaine supplementation on changes in hepatic metabolism of sulfur-containing amino acids and experimental cholestasis induced by alpha-naphthylisothiocyanate. Food Chem. Toxicol. 43: 663-670. *
Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T 2002 Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am. J. Gastroenterol. 97: 1849-1851. *
Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N 2006 Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J. Gastroenterol. 41: 686-692. *
Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y 2003 Protective role of hydroxysteroid sulfotransferase